Alliance A211601: Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion Study to Alliance Study A011502

Objective

This phase III trial evaluates mammographic breast density in participants with hormone receptor-negative breast cancer enrolled on study A011502. High breast density has been shown to be a strong risk factor for developing breast cancer and decreasing breast density may decrease the risk for breast cancer. Participants treated with aspirin may show reduced breast density on a mammogram.

https://clinicaltrials.gov/ct2/show/NCT03609021

Location: Essentia Health Cancer Centers

Research Study Categories

  • Adult Studies

Specialty

  • Breast Cancer
Contact
Cancer Clinical Trials at 844-681-7944
or cancertrials@essentiahelath.org

Like most websites, we use cookies and other technologies to keep our website reliable, secure, and to better understand how our site is used. By using our site, you agree to our use of these tools. Learn more.